Clinical Trial

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Study acronym: ILLUMINATE

Recruiting Phase 2

Summary

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)

Protocol Amendment History 7 changes

notable Trial sites expanded: 20 -> 24 locations 2026-07-28

notable Trial sites expanded: 11 -> 20 locations 2026-07-15

notable Trial sites expanded: 6 -> 11 locations 2026-06-23

notable Trial sites expanded: 3 -> 6 locations 2026-05-30

critical Recruitment opened 2026-04-22

notable Primary completion pushed: 2028-01-11 -> 2028-03-08 2026-04-22

minor Completion pushed: 2028-08-01 -> 2028-09-27 2026-04-22

Trial Details

NCT Number	NCT07318597
Lead Sponsor	Regeneron Pharmaceuticals
Conditions	Pulmonary Arterial Hypertension (PAH)
Enrollment	99 participants
Start Date	2026-05-06
Primary Completion	2028-02-27 (estimated)
Study Completion	2028-09-17 (estimated)
Updated on ClinicalTrials.gov	2026-08-05